Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study

According to data from a phase Ib, non-randomized, open-label study of ruxolitinib with nilotinib and prednisone in 15 patients with naïve or ruxolitinib-resistant myelofibrosis, this combination showed acceptable tolerability and relevant clinical activity. An overall response rate of 40% was noted at Cycle 7, and hyperglycemia was the most frequent treatment-related adverse event.